CGIM
ACAD icon

Cannon Global Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cannon Global Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-117,990
Closed -$2.17M – 79
2024
Q4 		$2.17M Buy
+117,990
New +$1.9M 4.7% 2

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Cannon Global Investment Management's ACAD Position: Q1 2025 in Review

Cannon Global Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 117,990 shares — an estimated $2.17M sold.

Cannon Global Investment Management first reported a position in ACAD in Q4 2024 and held it in 1 quarter. The position peaked at $2.17M in Q4 2024. 319 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Cannon Global Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 117,990 Acadia Pharmaceuticals shares in Q1 2025, an estimated $2.17M.
  • Cannon Global Investment Management first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Cannon Global Investment Management's Acadia Pharmaceuticals position peaked at $2.17M in Q4 2024.
  • 319 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Cannon Global Investment Management's 13F filing for Q1 2025, filed 28 Apr 2025.